<DOC>
	<DOCNO>NCT02404935</DOCNO>
	<brief_summary>National multicentric phase II trial evaluate whether single agent cetuximab effective maintenance therapy 8 cycle first line FOLFIRI plus cetuximab mCRC patient KRAS NRAS wild-type gene , assess progression-free survival 6 month start maintenance therapy .</brief_summary>
	<brief_title>Treatment After Irinotecan-based Frontline Therapy : Maintenance With Erbitux ( Patients wtRAS mCRC )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Histologically confirm colorectal cancer 2 . KRAS NRAS wildtype gene analysis mutation status primary tumour metastasis 3 . Non resectable metastatic disease curative intent 4 . No prior chemotherapy except fluoropyrimidines without oxaliplatinbased adjuvant treatment earlier 6 month ago inclusion date 5 . Patient present least one measurable tumour target ( great 20 mm ) accord RECIST criterion , never irradiate 6 . Patient great 3 month life expectancy 7 . Performance Status le equal 2 8 . Male female 18 year old 9 . Acceptable blood test 10 . Patient sign write informed consent form 1 . Known and/or symptomatic brain metastasis 2 . Known allergy one treatment components 3 . Neurological psychiatric condition could interfere good treatment compliance 4 . Patient currently treatment antitumour therapy : chemotherapy target therapy radiotherapy ≤ 14 day randomisation 5 . Other serious condition : respiratory failure . History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . 6 . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) 6 month enrolment/randomisation 7 . Concomitant severe infection . 8 . History cancer ( except skin cancer melanoma situ cervical epithelioma solid tumour treat curative purpose without sign condition treatment administer 5 year randomisation . ) 9 . Patient already include another clinical trial investigational molecule 10 . Prior treatment antiEGFr antibody ( e.g . panitumumab ( Vectibix® cetuximab / Erbitux® ) treatment small EGFr inhibitor molecule ( e.g. , erlotinib / Tarceva® ) 11 . Pregnant female , likely currently breast feeding , plan become pregnant within 6 month end treatment absence effective contraception male females childbearing age treatment 6 month ( male female ) end treatment 12 . Those deprive freedom guardianship 13 . Impossibility undergo trial 's medical followup geographical , social psychological reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>cetuximab</keyword>
	<keyword>maintenance</keyword>
</DOC>